Brentuximab Vedotin: A New Standard of Care Across All Lines of Therapy for Hodgkin Lymphoma - Cancer Therapy Advisor

Brentuximab Vedotin: A New Standard of Care Across All Lines of Therapy for Hodgkin Lymphoma

Chapter 1

High-Risk Hodgkin Lymphoma: Staging, Biologic Markers, and Management With Brentuximab Vedotin

Patrick J. Stiff, MD, of the Cardinal Bernardin Cancer Center in Maywood, Illinois, provides an overview of the staging, biologic markers, and other factors tied to risk for recurrence in patients with Hodgkin disease, and highlights the long-term remission achieved for many patients who received brentuximab vedotin.

Chapter 3

Brentuximab Vedotin: Role in Multiple Settings for Classical Hodgkin Lymphoma

Steven M. Ansell, MD, PhD, of the Mayo Clinic in Rochester, Minnesota, discusses the role of brentuximab vedotin in multiple settings for patients with classical Hodgkin lymphoma—in combination with chemotherapy as first- and second-line therapy, as consolidation for Hodgkin patients at risk for recurrence following an autologous hematopoietic stem cell transplant, and as treatment post-autologous transplant for relapsed/refractory patients.

Chapter 4

The AETHERA Trial: Reducing the Risk for Recurrence

John W. Sweetenham, MD, Senior Director of Clinical Affairs at the Huntsman Cancer Institute, University of Utah in Salt Lake City, Utah, analyses the results of the pivotal AETHERA trial of brentuximab vedotin for patients with Hodgkin lymphoma who are at risk of relapse following an autologous stem cell transplant.

Next hm-playlist in Lymphoma